Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment 1% in Subjects With Actinic Keratosis on the Face or Scalp
Sponsor: Almirall, S.A.
A PHASE2 clinical study on Actinic Keratosis, this trial is completed. The trial is conducted by Almirall, S.A. and has accumulated 11 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2021 [monthly]
Completed PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Feb 2019 — Jun 2020 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jan 2019 — Feb 2019 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — May 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Almirall, S.A.
- Athenex, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .